This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute myeloid leukemia (AML)	Mitochondrial translation	<p><i>In vitro</i> and mouse studies suggest Tygacil tigecycline could be repurposed to help treat AML. In xenograft mouse models of AML, Tygacil decreased mitochondrial translation, tumor size and leukemic engraftment compared with vehicle. Ongoing work includes a Phase I trial of Tygacil to treat AML.</p> <p>Tygacil tigecycline, a glycylcycline antibiotic from Pfizer Inc. that inhibits the bacterial ribosome, is approved to treat abdominal infection, skin and skin structure infection (SSSI) and pneumonia. Generic daunorubicin is marketed to treat AML and acute lymphocytic leukemia (ALL). Generic cytarabine is marketed to treat AML and non-Hodgkin's lymphoma (NHL).</p> <p>SciBX 4(46); doi:10.1038/scibx.2011.1286 Published online Dec. 1, 2011</p>	Patented by the University Health Network; available for licensing or partnering	<p>Škrtić, M. <i>et al. Cancer Cell</i>; published online Nov. 15, 2011; doi:10.1016/j.ccr.2011.10.015</p> <p>Contact: Aaron D. Schimmer, Ontario Cancer Institute, Toronto, Ontario, Canada e-mail: aaron.schimmer@utoronto.ca</p>